Table 3.
Treatment, quality indicators, and postoperative complications (ns, not specified; TaTME, transanal total mesorectal excision)
| Study cohort | |||
|---|---|---|---|
| TaTME patients | |||
| n | % | ||
| Neoadjuvant therapy | Yes | 273 | 72.2 |
| No | 105 | 27.8 | |
| Adjuvant therapy | Yes | 227 | 60.1 |
| No | 151 | 39.9 | |
| Lymph nodes harvested | < 12 | 43 | 11.4 |
| ≥ 12 | 330 | 87.3 | |
| ns | 5 | 1.3 | |
| Residual tumor local | R0 | 364 | 96.3 |
| R1/2 | 13 | 3.4 | |
| RX/ns | 1 | 0.3 | |
| Reoperation (30 days) | Yes | 11 | 2.9 |
| No | 367 | 97.1 | |
| Clavien–Dindo | No complication | 86 | 22.8 |
| Grade I | 22 | 5.8 | |
| Grade II | 37 | 9.8 | |
| Grade III | 41 | 10.8 | |
| Grade IV | 9 | 2.4 | |
| Grade V | 4 | 1.1 | |
| ns | 179 | 47.4 | |
| Anastomotic leak (30 days) | Yes | 19 | 5.0 |
| No | 359 | 95.0 | |
| Presacral abscess (30 days) | Yes | 12 | 3.2 |
| No | 366 | 96.8 | |
| Total | 378 | 100.0 | |